Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Evotec

Market Cap 868M 1.01B 799M 750M 1.41B 95.19B 1.42B 9.45B 3.69B 46.62B 3.78B 3.7B 161B P/E Ratio 2026 *
-6.87x
P/E Ratio 2027 * -25x
Enterprise Value 882M 1.02B 812M 762M 1.43B 96.76B 1.45B 9.6B 3.75B 47.38B 3.84B 3.76B 164B EV / Sales 2026 *
1.2x
EV / Sales 2027 * 1.15x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 70 2024-06-09
Director/Board Member 58 2019-06-18
Chairman 65 2026-06-10
Change 5-day change 1-year change 3-year change Capi.($)
+8.33%-.--% - - 981M
+0.96%+1.16%-12.97%-12.33% 43.03B
+4.02%+7.79%+294.33%+536.67% 32.71B
-1.69%-2.89%+13.70%-17.71% 30.29B
+1.41%-0.96%-0.53%+33.41% 29.4B
+1.16%+9.79%+14.27%+22.28% 25.08B
+2.40%+8.49% - - 13.54B
+0.03%+2.10%+56.75%+111.91% 13.35B
-1.09%-2.31%+5.07%+5.00% 12.97B
+0.93%+0.57%+107.81%+77.40% 12.11B
Average +1.65%+1.60%+59.80%+94.58% 23.61B
Weighted average by Cap. +1.08%+1.76%+60.10%+103.18%

Financials

2026 *2027 *
Net sales 738M 856M 679M 637M 1.2B 80.88B 1.21B 8.03B 3.13B 39.61B 3.21B 3.14B 137B 818M 949M 753M 706M 1.33B 89.67B 1.34B 8.9B 3.48B 43.91B 3.56B 3.49B 152B
Net income -113M -131M -104M -97.76M -184M -12.42B -185M -1.23B -481M -6.08B -493M -483M -21.04B -30.42M -35.3M -28M -26.27M -49.34M -3.34B -49.83M -331M -129M -1.63B -132M -130M -5.65B
Net Debt 14.3M 16.59M 13.16M 12.35M 23.19M 1.57B 23.42M 156M 60.78M 768M 62.26M 60.94M 2.66B 69.32M 80.43M 63.8M 59.85M 112M 7.6B 114M 754M 295M 3.72B 302M 295M 12.88B
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.884EUR
Average target price
6.443EUR
Spread / Average Target
+31.92%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!